Literature DB >> 22705888

Preventing platelet thrombosis with a PAR1 pepducin.

Ahmed Abdel-Latif, Susan S Smyth.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22705888      PMCID： PMC3926097          DOI： 10.1161/CIRCULATIONAHA.112.122317

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  13 in total

1.  Heart disease and stroke statistics--2011 update: a report from the American Heart Association.

Authors:  Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Robert J Adams; Jarett D Berry; Todd M Brown; Mercedes R Carnethon; Shifan Dai; Giovanni de Simone; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Kurt J Greenlund; Susan M Hailpern; John A Heit; P Michael Ho; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Mary M McDermott; James B Meigs; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Wayne D Rosamond; Paul D Sorlie; Randall S Stafford; Tanya N Turan; Melanie B Turner; Nathan D Wong; Judith Wylie-Rosett
Journal:  Circulation       Date:  2010-12-15       Impact factor: 29.690

2.  Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin.

Authors:  Ping Zhang; András Gruber; Shogo Kasuda; Carey Kimmelstiel; Katie O'Callaghan; Daniel H Cox; Andrew Bohm; James D Baleja; Lidija Covic; Athan Kuliopulos
Journal:  Circulation       Date:  2012-06-15       Impact factor: 29.690

3.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.

Authors: 
Journal:  BMJ       Date:  2002-01-12

4.  Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes Trial.

Authors:  Michelle L O'Donoghue; Deepak L Bhatt; Stephen D Wiviott; Shaun G Goodman; Desmond J Fitzgerald; Dominick J Angiolillo; Shinya Goto; Gilles Montalescot; Uwe Zeymer; Philip E Aylward; Victor Guetta; Dariusz Dudek; Rafal Ziecina; Charles F Contant; Marcus D Flather
Journal:  Circulation       Date:  2011-04-18       Impact factor: 29.690

5.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

6.  Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome.

Authors:  Shinya Goto; Tetsu Yamaguchi; Yasuo Ikeda; Kenichi Kato; Hiroya Yamaguchi; Peder Jensen
Journal:  J Atheroscler Thromb       Date:  2010-02-03       Impact factor: 4.928

Review 7.  Thrombin formation.

Authors:  Kenneth G Mann
Journal:  Chest       Date:  2003-09       Impact factor: 9.410

8.  Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease.

Authors:  Shinya Goto; Hisao Ogawa; Masaru Takeuchi; Marcus D Flather; Deepak L Bhatt
Journal:  Eur Heart J       Date:  2010-08-30       Impact factor: 29.983

9.  Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study.

Authors:  Richard C Becker; David J Moliterno; Lisa K Jennings; Karen S Pieper; Jinglan Pei; Alan Niederman; Khaled M Ziada; Gail Berman; John Strony; Diane Joseph; Kenneth W Mahaffey; Frans Van de Werf; Enrico Veltri; Robert A Harrington
Journal:  Lancet       Date:  2009-03-14       Impact factor: 79.321

10.  Thrombin functions during tissue factor-induced blood coagulation.

Authors:  Kathleen E Brummel; Sara G Paradis; Saulius Butenas; Kenneth G Mann
Journal:  Blood       Date:  2002-07-01       Impact factor: 22.113
View more
  2 in total

1.  Impact of supervised beego, a traditional Chinese water-only fasting, on thrombosis and haemostasis.

Authors:  Yixuan Fang; Yue Gu; Chen Zhao; Yaqi Lv; Jiawei Qian; Lingjiang Zhu; Na Yuan; Suping Zhang; Li Wang; Mengli Li; Qing Zhang; Li Xu; Wen Wei; Lei Li; Li Ji; Xueqin Gao; Jingyi Zhang; Yueping Shen; Zixing Chen; Guanghui Wang; Kesheng Dai; Jianrong Wang
Journal:  BMJ Nutr Prev Health       Date:  2021-01-05

Review 2.  Significance of antiplatelet therapy in emergency myocardial infarction treatment.

Authors:  Anna Komosa; Maciej Lesiak; Andrzej Siniawski; Tatiana Mularek-Kubzdela; Stefan Grajek
Journal:  Postepy Kardiol Interwencyjnej       Date:  2014-03-23       Impact factor: 1.426
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.